Target intelligence / Profile preview

DNA-directed RNA polymerase I subunit F (POLR1F)

Target
POLR1F
Molecular classification
Enzyme, RNA polymerase, Transcriptional machinery
01

Overview

DNA-directed RNA polymerase I subunit F (POLR1F) is a core component of the multi-subunit enzyme RNA polymerase I, which is specialized for the transcription of ribosomal RNA (rRNA) genes in the nucleolus[1][2][3]. The enzyme transcribes a single pre-rRNA precursor that is processed into the main rRNA components of the ribosome, thereby playing an essential role in ribosome biogenesis and cellular homeostasis. POLR1F (also known as RPA43 or TWISTNB) forms part of the smaller stalk complex, crucial for assembly and function of the polymerase complex[2][3]. Upregulation or mutation of this subunit and its associated machinery is linked to diseases such as cancer, ribosomopathies, and developmental disorders. Given its central role in cell proliferation and protein synthesis, RNA polymerase I — including its subunits like POLR1F — is a therapeutic target in oncology, with specific small-molecule inhibitors under investigation. Its function and clinical importance make it a key enzyme in both biological regulation and disease processes[2][3].

Other names
DNA-directed RNA polymerase I subunit RPA43RPA43TWISTNBA43Twist neighbor protein
02

Mechanism of action

Inhibition of rRNA transcription, Disruption of ribosome biogenesis, Induction of nucleolar stress leading to cell cycle arrest and apoptosis in rapidly dividing cells

03

Biological functions

Ribosomal RNA (rRNA) synthesisTranscriptionRibosome biogenesisRegulation of cell growth and proliferation
04

Disease associations

CancerRibosomopathiesDevelopmental disorders (e.g., Treacher Collins syndrome, acrofacial dysostosis)Aging-related disorders
05

Safety considerations

Potential impact on normal ribosome biogenesis in healthy proliferating cellsMyelosuppressionOff-target effects in non-cancerous tissuesDevelopmental toxicity
06

Interacting drugs

Small-molecule inhibitors of RNA polymerase I (some in clinical trials; specific drugs include CX-5461)
07

Biomarkers

Upregulation or mutation associated with cancer and certain developmental syndromes (e.g., can serve as markers in cancer biology and ribosomopathy diagnostics)

Beyond the preview

Go deeper on DNA-directed RNA polymerase I subunit F (POLR1F).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA-directed RNA polymerase I subunit F (POLR1F).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call